Abbott India Share Price
Sector: Biotechnology & Drugs
29732.50 -15.40 (-0.05%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
29323.45
Today’s High
29866
52 Week Low
25200.05
52 Week High
31900
29795.00 +90.00 (0.30%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
29450
Today’s High
29945
52 Week Low
25200
52 Week High
31898.95
Key Metrics
- Market Cap (In Cr) 63100.79
- Beta 0.01
- Div. Yield (%) 1.38
- P/B 17.06
- TTM P/E 47.36
- Peg Ratio 2.33
- Sector P/E 26.62
- Open Price 29323.45
- Prev Close 29747.9
Abbott India Analysis
Price Analysis
-
1 Week-3.21%
-
3 Months8.88%
-
6 Month4.19%
-
YTD-0.12%
-
1 Year15.7%
Risk Meter
- 26% Low risk
- 26% Moderate risk
- 26% Balanced Risk
- 26% High risk
- 26% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 3
- 3
- 2
- 2
- Buy
- 2
- 2
- 2
- 2
- Hold
- 0.00
- 0.00
- 0.00
- 0.00
- Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Strong Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Total
- 5
- 5
- 4
- 4
Abbott India News
Recommended stocks to watch: Top 8 stock picks by market experts for 25 February
2 min read . 25 Feb 2025Stocks to buy today: MarketSmith India’s top stock picks for 25 February
3 min read . 25 Feb 2025Q3 Results today: Swiggy, Info Edge, Reliance Power, others to announce results
2 min read . 05 Feb 2025Abbott India Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 5848.91
- Selling/ General/ Admin Expenses Total
- 1118.08
- Depreciation/ Amortization
- 71.17
- Other Operating Expenses Total
- 25.07
- Total Operating Expense
- 4463.28
- Operating Income
- 1385.63
- Net Income Before Taxes
- 1617.75
- Net Income
- 1201.22
- Diluted Normalized EPS
- 565.24
- Period
- 2024
- Total Assets
- 5193.49
- Total Liabilities
- 1494.6
- Total Equity
- 3698.89
- Tangible Book Valueper Share Common Eq
- 1737.58
- Period
- 2024
- Cashfrom Operating Activities
- 1212.81
- Cashfrom Investing Activities
- -416.03
- Cashfrom Financing Activities
- -744.71
- Net Changein Cash
- 52.07
- Period
- 2023
- Total Revenue
- 5348.73
- Selling/ General/ Admin Expenses Total
- 1069.93
- Depreciation/ Amortization
- 69.97
- Other Operating Expenses Total
- 66.33
- Total Operating Expense
- 4206.75
- Operating Income
- 1141.98
- Net Income Before Taxes
- 1273.82
- Net Income
- 949.41
- Diluted Normalized EPS
- 446.68
- Period
- 2023
- Total Assets
- 4555.51
- Total Liabilities
- 1366.97
- Total Equity
- 3188.54
- Tangible Book Valueper Share Common Eq
- 1497
- Period
- 2023
- Cashfrom Operating Activities
- 893.39
- Cashfrom Investing Activities
- -147.71
- Cashfrom Financing Activities
- -638.72
- Net Changein Cash
- 106.96
- Period
- 2022
- Total Revenue
- 4919.27
- Selling/ General/ Admin Expenses Total
- 1086.89
- Depreciation/ Amortization
- 66.1
- Other Operating Expenses Total
- 57.26
- Total Operating Expense
- 3892.34
- Operating Income
- 1026.93
- Net Income Before Taxes
- 1079.73
- Net Income
- 798.7
- Diluted Normalized EPS
- 375.87
- Period
- 2022
- Total Assets
- 4224.12
- Total Liabilities
- 1404.33
- Total Equity
- 2819.79
- Tangible Book Valueper Share Common Eq
- 1322.94
- Period
- 2022
- Cashfrom Operating Activities
- 947.66
- Cashfrom Investing Activities
- -395.84
- Cashfrom Financing Activities
- -637.38
- Net Changein Cash
- -85.56
- Period
- 2021
- Total Revenue
- 4310.02
- Selling/ General/ Admin Expenses Total
- 918.82
- Depreciation/ Amortization
- 58.13
- Other Operating Expenses Total
- 53.77
- Total Operating Expense
- 3441.5
- Operating Income
- 868.52
- Net Income Before Taxes
- 925.95
- Net Income
- 690.69
- Diluted Normalized EPS
- 325.12
- Period
- 2021
- Total Assets
- 3840.45
- Total Liabilities
- 1238.29
- Total Equity
- 2602.16
- Tangible Book Valueper Share Common Eq
- 1224.04
- Period
- 2021
- Cashfrom Operating Activities
- 726.74
- Cashfrom Investing Activities
- -71.82
- Cashfrom Financing Activities
- -581.79
- Net Changein Cash
- 73.13
- Period
- 2020
- Total Revenue
- 4093.14
- Selling/ General/ Admin Expenses Total
- 929.42
- Depreciation/ Amortization
- 59.61
- Other Operating Expenses Total
- 59.3
- Total Operating Expense
- 3386.48
- Operating Income
- 706.66
- Net Income Before Taxes
- 802.69
- Net Income
- 592.93
- Diluted Normalized EPS
- 279.22
- Period
- 2020
- Total Assets
- 3546.85
- Total Liabilities
- 1115.14
- Total Equity
- 2431.71
- Tangible Book Valueper Share Common Eq
- 1143.95
- Period
- 2020
- Cashfrom Operating Activities
- 626.11
- Cashfrom Investing Activities
- -401.19
- Cashfrom Financing Activities
- -216.79
- Net Changein Cash
- 8.13
- Period
- 2019
- Total Revenue
- 3678.6
- Selling/ General/ Admin Expenses Total
- 914.55
- Depreciation/ Amortization
- 16.92
- Other Operating Expenses Total
- 47
- Total Operating Expense
- 3085.21
- Operating Income
- 593.4
- Net Income Before Taxes
- 698.85
- Net Income
- 450.33
- Diluted Normalized EPS
- 209
- Period
- 2019
- Total Assets
- 2940.91
- Total Liabilities
- 932.33
- Total Equity
- 2008.59
- Tangible Book Valueper Share Common Eq
- 944.38
- Period
- 2019
- Cashfrom Operating Activities
- 499.13
- Cashfrom Investing Activities
- -257
- Cashfrom Financing Activities
- -142.8
- Net Changein Cash
- 99.33
- Period
- 2024-12-31
- Total Revenue
- 1614.28
- Selling/ General/ Admin Expenses Total
- 134.68
- Depreciation/ Amortization
- 17.99
- Other Operating Expenses Total
- 150.81
- Total Operating Expense
- 1196.18
- Operating Income
- 418.1
- Net Income Before Taxes
- 487.59
- Net Income
- 360.78
- Diluted Normalized EPS
- 169.78
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 1632.67
- Selling/ General/ Admin Expenses Total
- 147.4
- Depreciation/ Amortization
- 17.51
- Other Operating Expenses Total
- 144.55
- Total Operating Expense
- 1211.22
- Operating Income
- 421.45
- Net Income Before Taxes
- 479.43
- Net Income
- 358.61
- Diluted Normalized EPS
- 168.76
- Period
- 2024-09-30
- Total Assets
- 5063.02
- Total Liabilities
- 1541.91
- Total Equity
- 3521.11
- Tangible Book Valueper Share Common Eq
- 1653.31
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 481.95
- Cashfrom Investing Activities
- 762.53
- Cashfrom Financing Activities
- -898.53
- Net Changein Cash
- 345.95
- Period
- 2024-06-30
- Total Revenue
- 1557.61
- Selling/ General/ Admin Expenses Total
- 161.06
- Depreciation/ Amortization
- 18.37
- Other Operating Expenses Total
- 159.18
- Total Operating Expense
- 1184.97
- Operating Income
- 372.64
- Net Income Before Taxes
- 437.22
- Net Income
- 328.01
- Diluted Normalized EPS
- 154.36
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 1438.63
- Selling/ General/ Admin Expenses Total
- 145.24
- Depreciation/ Amortization
- 18.19
- Other Operating Expenses Total
- 157.96
- Total Operating Expense
- 1127.29
- Operating Income
- 311.34
- Net Income Before Taxes
- 389.68
- Net Income
- 287.06
- Diluted Normalized EPS
- 135.11
- Period
- 2024-03-31
- Total Assets
- 5193.49
- Total Liabilities
- 1494.6
- Total Equity
- 3698.89
- Tangible Book Valueper Share Common Eq
- 1737.58
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 1212.81
- Cashfrom Investing Activities
- -416.03
- Cashfrom Financing Activities
- -744.71
- Net Changein Cash
- 52.07
- Period
- 2023-12-31
- Total Revenue
- 1437.14
- Selling/ General/ Admin Expenses Total
- 139.19
- Depreciation/ Amortization
- 17.97
- Other Operating Expenses Total
- 133.47
- Total Operating Expense
- 1067.42
- Operating Income
- 369.72
- Net Income Before Taxes
- 422.16
- Net Income
- 310.98
- Diluted Normalized EPS
- 146.34
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 1494.14
- Selling/ General/ Admin Expenses Total
- 142.7
- Depreciation/ Amortization
- 17.84
- Other Operating Expenses Total
- 156.21
- Total Operating Expense
- 1131.1
- Operating Income
- 363.04
- Net Income Before Taxes
- 415.42
- Net Income
- 312.94
- Diluted Normalized EPS
- 147.27
- Period
- 2023-09-30
- Total Assets
- 4515.94
- Total Liabilities
- 1407.02
- Total Equity
- 3108.92
- Tangible Book Valueper Share Common Eq
- 1459.82
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 683.63
- Cashfrom Investing Activities
- 372.22
- Cashfrom Financing Activities
- -717.39
- Net Changein Cash
- 338.46
- Period
- 2023-06-30
- Total Revenue
- 1479
- Selling/ General/ Admin Expenses Total
- 149.45
- Depreciation/ Amortization
- 17.17
- Other Operating Expenses Total
- 150.98
- Total Operating Expense
- 1141.17
- Operating Income
- 337.83
- Net Income Before Taxes
- 390.49
- Net Income
- 290.24
- Diluted Normalized EPS
- 136.58
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 1338.4
- Selling/ General/ Admin Expenses Total
- 126.7
- Depreciation/ Amortization
- 17.34
- Other Operating Expenses Total
- 176.2
- Total Operating Expense
- 1080.3
- Operating Income
- 258.1
- Net Income Before Taxes
- 308.41
- Net Income
- 231.42
- Diluted Normalized EPS
- 108.92
- Period
- 2023-03-31
- Total Assets
- 4555.51
- Total Liabilities
- 1366.97
- Total Equity
- 3188.54
- Tangible Book Valueper Share Common Eq
- 1497
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 893.39
- Cashfrom Investing Activities
- -147.71
- Cashfrom Financing Activities
- -638.72
- Net Changein Cash
- 106.96
- Period
- 2022-12-31
- Total Revenue
- 1326.48
- Selling/ General/ Admin Expenses Total
- 135.24
- Depreciation/ Amortization
- 17.81
- Other Operating Expenses Total
- 129.89
- Total Operating Expense
- 1027.8
- Operating Income
- 298.68
- Net Income Before Taxes
- 334.83
- Net Income
- 246.83
- Diluted Normalized EPS
- 116.16
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Abbott India Technical
Moving Average
SMA
- 5 Day30419.82
- 10 Day30321.09
- 20 Day30169.77
- 50 Day30028.26
- 100 Day29153.07
- 300 Day28805.94
Abbott India Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Lupin
- 2107
- 88.65
- 4.39
- 2403.45
- 1493.75
- 96162.53
- Zydus Lifesciences
- 885
- 25.9
- 3.01
- 1323.9
- 797.05
- 89020.62
- Abbott India
- 29732.5
- -15.4
- -0.05
- 31900
- 25200.05
- 63100.79
- Alkem Laboratories
- 5017.1
- -18.65
- -0.37
- 6440
- 4409.9
- 59981.59
- Glaxosmithkline Pharmaceutical
- 2858.8
- 54.75
- 1.95
- 3147.45
- 1869.14
- 48487.73
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Lupin
- 44.52
- 6.44
- 2.51
- 2.04
- Zydus Lifesciences
- 22.67
- 4.36
- 15.65
- 14.33
- Abbott India
- 52.55
- 17.06
- 30.46
- 17.26
- Alkem Laboratories
- 33.46
- 5.84
- 18.26
- 13.94
- Glaxosmithkline Pharmaceutical
- 68.5
- 26.71
- 20.45
- 12.25
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 05-Feb-25
- Quarterly Results
- 07-Nov-24
- Quarterly Results
- 07-Aug-24
- Quarterly Results
- 09-May-24
- Audited Results & Final Dividend
- 01-Feb-24
- Quarterly Results
- 09-Nov-23
- Quarterly Results
- 09-Aug-23
- Quarterly Results
- 19-May-23
- Audited Results & Final Dividend
- 10-Feb-23
- Quarterly Results
- 14-Nov-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 08-Aug-24
- 09-May-24
- AGM
- 09-Aug-23
- 19-May-23
- AGM
- 10-Aug-22
- 17-May-22
- AGM
- 28-Mar-22
- 23-Feb-22
- POM
- 27-Jul-21
- 18-May-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 09-May-24
- 19-Jul-24
- 19-Jul-24
- 410
- 19-May-23
- 21-Jul-23
- 21-Jul-23
- 180
- 20-May-23
- 21-Jul-23
- 21-Jul-23
- 145
- 17-May-22
- -
- 02-Aug-22
- 145
- 18-May-22
- -
- 02-Aug-22
- 130
- 18-May-21
- -
- 19-Jul-21
- 120
- 19-May-21
- -
- 19-Jul-21
- 155


